Catalyst Pharmaceuticals Inc (CPRX) Receives Consensus Rating of “Buy” from Brokerages

Shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) have received a consensus rating of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $8.13.

Several research analysts recently weighed in on CPRX shares. Zacks Investment Research cut shares of Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 13th. BidaskClub upgraded shares of Catalyst Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, February 14th. Cantor Fitzgerald restated a “buy” rating and issued a $10.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Tuesday, March 19th. ValuEngine upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, March 25th. Finally, HC Wainwright set a $9.00 price target on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Opaleye Management Inc. bought a new position in Catalyst Pharmaceuticals during the first quarter valued at approximately $9,308,000. SEI Investments Co bought a new position in Catalyst Pharmaceuticals during the first quarter valued at approximately $572,000. Geode Capital Management LLC grew its position in Catalyst Pharmaceuticals by 7.8% during the first quarter. Geode Capital Management LLC now owns 1,146,422 shares of the biopharmaceutical company’s stock valued at $5,846,000 after acquiring an additional 82,654 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Catalyst Pharmaceuticals by 8.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 226,188 shares of the biopharmaceutical company’s stock valued at $1,154,000 after acquiring an additional 17,784 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Catalyst Pharmaceuticals by 5.8% during the first quarter. The Manufacturers Life Insurance Company now owns 67,107 shares of the biopharmaceutical company’s stock valued at $342,000 after acquiring an additional 3,702 shares during the last quarter. Institutional investors and hedge funds own 47.85% of the company’s stock.

CPRX stock opened at $3.54 on Thursday. The company has a current ratio of 6.08, a quick ratio of 5.80 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $325.02 million, a P/E ratio of -10.73 and a beta of 2.43. Catalyst Pharmaceuticals has a 1-year low of $1.85 and a 1-year high of $6.16.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings data on Monday, May 13th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.12. The company had revenue of $12.45 million during the quarter, compared to the consensus estimate of $2.40 million. During the same quarter last year, the company posted ($0.06) earnings per share. As a group, sell-side analysts predict that Catalyst Pharmaceuticals will post -0.24 earnings per share for the current year.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.

See Also: Market Capitalization and Individual Investors

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.